Boca Raton, FL, July 31, 2024 (GLOBE NEWSWIRE) -- Janover Inc. (Nasdaq:  JNVR) ("Janover" or the "Company"), an AI-enabled platform for commercial real estate transactions, today provided an update on Janover Insurance Group ("Janover Insurance"), its insurtech subsidiary for commercial property insurance and more. The Company officially launched Janover Insurance in March 2024 and is pleased to report that Janover Insurance achieved profitability in May 2024. Our total monthly recurring revenue for the mon ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:VMEO) Vimeo, the world's most innovative video experience platform for creators and enterprises, today announced the launch of its AI-powered video translation solution. Leveraging generative AI to translate video, audio and captions into dozens of languages - while replicating the original speakers' voices - the new solution dramatically reduces the time and cost associated with traditional translation offerings. Scaling videos to reach global audiences t ...

BEIJING, July 31, 2024 (GLOBE NEWSWIRE) -- Global Mofy Metaverse Limited (the "Company" or "Global Mofy") (NASDAQ:GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that CEO Mr. Haogang Yang, invited by NVIDIA China, concluded his participation at SIGGRAPH 2024 in Denver, Colorado. This prominent event, supported by NVIDIA, offered Mr. Yang the invaluable op ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 15,849,056 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggr ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio webcast of the present ...

文章核心观点 - 公司推出了一种新型的神经退行性疾病治疗药物候选物morADC(Morphomer® Antibody Drug Conjugates),该技术平台结合了公司的SupraAntigen®和Morphomer®两大技术平台的优势[1][2][3] - morADC能够显著提高小分子Morphomer在中枢神经系统的穿透力和抑制蛋白聚集的效力,相比单独使用抗体或小分子效果更佳[2][3] - morADC可以实现单靶点或双靶点策略,针对阿尔兹海默症、帕金森病等多种神经退行性疾病的关键靶点如Abeta、Tau和α-突触核蛋白进行治疗[2] - 公司有信心morADC技术平台是一个突破性时刻,有望成为首创和最佳的治疗候选物,为患者带来更好的临床结果[3] 公司概况 - 公司是一家临床阶段的生物制药公司,专注于神经退行性疾病的精准医疗,包括阿尔兹海默症、帕金森病等[6] - 公司拥有两大临床验证的技术平台SupraAntigen®和Morphomer®,支撑公司广泛多样的管线,目前有16个治疗和诊断项目,其中5个处于2期临床试验,1个处于3期[6] - 公司与全球领先制药公司建立了多个战略合作伙伴关系,获得了大量非稀释性资金,包括里程碑付款和版税[6] 技术平台 - SupraAntigen®平台用于发现和开发主动免疫疗法(疫苗)和被动免疫疗法(单克隆抗体)[3] - Morphomer®平台结合小分子化学和专有生物学检测方法,可以识别和开发针对细胞内外病理性蛋白聚集的小分子Morphomer[3] - 通过将Morphomer小分子连接到SupraAntigen抗体形成morADC,结合了两大平台的优势,提高了穿透血脑屏障的能力和疗效[4][5]

Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report second quarter 2024 financial results and provide a business update on August 7, 2024, after the close of the market. The announcement will b ...

GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defi ...

For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously announced in February. Celularity's expected combined net sales for the first half 2024 are $25.8 to $27.8 million compared to $6.9 million of net sales in the first of 2023 at the midpoint of the 2024 range. Celularity reiterated it is on track to file a 510(k) premarket submission for its ...

Location Primarily Dedicated to Manufacturing Company's New Pop & Go™ Freeze Pops Company Has Recently Added Three New Third Party Locations Dramatically Boosting Annual Capacity to Over 120 million Units LOS ANGELES, July 31, 2024 (GLOBE NEWSWIRE) -- Barfresh Food Group Inc. (the "Company" or "Barfresh") (NASDAQ:BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today announced a new co-manufacturing location. This new location will primarily be dedicated to manufacturing the Company ...